AbbVie, Actavis, Solvay generics, genitourinary news

The U.S. Supreme Court ruled in Federal Trade Commission v. Actavis Inc., et al. that pay-for-delay settlements between branded and generic drug manufacturers are not immune from antitrust litigation. The decision